Rimonabant for neurocognition in schizophrenia: A 16-week double blind randomized placebo controlled trial

Abstract: Objective: To examine the effect of rimonabant on neurocognitive impairments in people with schizophrenia. Methods: Participants entered a 16-week double-blind, placebo-controlled, randomized clinical trial. A neurocognitive battery was administered at baseline and end of study. Results: In comparison to rimonabant (20mg/day), placebo-treated participants exhibited a significant improvement on the Repeatable Battery for the Assessment of Neuropsychological Status total score. In contrast, rimonabant was associated with significant improvement on a probabilistic learning task. There were no other significant treatment effects. Conclusions: Rimonabant did not improve global cognitive functioning, but did improve a specific learning deficit based on response to positive feedback. [Copyright &y& Elsevier]

Copyright of Schizophrenia Research is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)